Financials
9M and Q3 2024 Results | Nov. 12, 2024 |
Half-year Report | Jul. 25, 2024 |
1st Quarter Results | Apr. 25, 2024 |
9M and Q3 2023 results | Nov. 09, 2023 |
Half-year Report | Jul. 28, 2023 |
1st Quarter Results | Apr. 27, 2023 |
AZ 2022 Annual Report XBRL | Feb. 21, 2023 |
Proxies
Special Business Approved at AGM | Apr. 12, 2024 |
Proxy Form for 2024 AGM | Mar. 07, 2024 |
Notice of AGM | Mar. 07, 2024 |
Notice of AGM | Mar. 07, 2024 |
Special Business Approved at AGM | Apr. 27, 2023 |
Result of AGM | Apr. 27, 2023 |
Notice of AGM | Mar. 22, 2023 |
Ownership Update
Director/PDMR Shareholding | Nov. 20, 2024 |
Director/PDMR Shareholding | Nov. 15, 2024 |
Director/PDMR Shareholding | Nov. 15, 2024 |
Director/PDMR Shareholding | Nov. 13, 2024 |
Director/PDMR Shareholding | Jun. 12, 2024 |
Director/PDMR Shareholding | May. 15, 2024 |
Director/PDMR Shareholding | Mar. 12, 2024 |
Announcements
Block listing Interim Review | Dec. 02, 2024 |
Total Voting Rights | Dec. 02, 2024 |
Truqap improved rPFS in advanced prostate cancer | Nov. 25, 2024 |
Tagrisso recommended for EU approval - LAURA | Nov. 18, 2024 |
AstraZeneca invests $3.5 billion in US | Nov. 12, 2024 |
KOMET Phase III trial met primary endpoint | Nov. 12, 2024 |
Dato-DXd new BLA submitted, NSQ BLA withdrawn | Nov. 12, 2024 |
Prospectuses
AstraZeneca prices a €1.4bn bond offering | Jul. 30, 2024 |
AstraZeneca prices a $5bn bond offering | Feb. 22, 2024 |
AstraZeneca prices a $2.25bn bond offering | Mar. 01, 2023 |
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | Jun. 15, 2022 |
AstraZeneca prices a EUR800m bond offering | May. 27, 2021 |
AstraZeneca prices a $7bn bond offering | May. 26, 2021 |
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | May. 24, 2021 |